(Total Views: 413)
Posted On: 08/29/2019 1:12:07 PM
Post# of 154901
Re: the lawman #6905
I respect your opinion, but I think you’re underestimating the cost of replacing NP.
“but to preferably replace Pourhasssan with a seasoned CEO who can help guide the company in a competent and professional manner.
You're upset with NP’s compensation but want to replace him with a seasoned CEO who I’m assuming would have biotech ad drug approval experience. That will not be cheap and it will not change the path of leronlimab or increase the revenues that leronlimab will bring in, IMO. I don’t think many CEOs would be willing to state that they’d bring a company more revenues, especially a biotech that requires a lengthy FDA process for approval.
“but to preferably replace Pourhasssan with a seasoned CEO who can help guide the company in a competent and professional manner.
You're upset with NP’s compensation but want to replace him with a seasoned CEO who I’m assuming would have biotech ad drug approval experience. That will not be cheap and it will not change the path of leronlimab or increase the revenues that leronlimab will bring in, IMO. I don’t think many CEOs would be willing to state that they’d bring a company more revenues, especially a biotech that requires a lengthy FDA process for approval.
(1)
(0)
